Using PD-L1 as a Biomarker of Response

Video

Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.

Clinical Pearls

Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.

  • There remains a need to determine the utility of PD-L1 as a biomarker of response to PD-1-inhibiting agents.
  • Patients with high levels of PD-L1 within their tumor are more likely to respond to PD-1-inhibiting agents.
  • Patients that do not express PD-L1 can still benefit from PD-1 blockade.
  • Regardless of PD-L1 status, patients will be given the option of being treated with PD-1-inhibiting agents until more data are available.
Related Videos
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Related Content